Elizabeth Wang Rose Hills
Evaluating the 3,4,3-LI(1,2-HOPO) Chelator as a Gadolinium Decorporation Agent
Gadolinium-based contrast agents (GBCAs), consisting of a chelating agent and gadolinium metal (Gd(III)), have been used to enhance magnetic resonance imaging (MRI) contrast for the last 30 years, with over 300 million procedures to date. Because of the electronic magnetic moment of the gadolinium and nearby water molecules, gadolinium can be imaged accurately when exposed to strong electromagnetic fields like those created by MRI machines, improving the image clarity of the bodys structures. Accurate diagnosis scans allow for the detection of inflammation, tumors, blood vessels, and blood supply, all of which are crucial in detecting life threatening illnesses. Unfortunately, recent studies suggest that the in vivo instability of GBCAs has led to the dissociation of Gd(III) from their chelated complexes. In addition to accumulating in patients bone and brain tissue, free Gd(III) damages kidneys and compromises renal functions. With a more stable Gd(III)-chelate complex, the free Gd(III) could be reduced, lowering the Gd(III) deposition in the body. In this study, we will be evaluating the efficacy of the ligand 3,4,3-LI(1,2-HOPO) at removing residual Gd deposited from various Gd(III) chelating agents used in todays clinical formulations.